Invention:
This innovation introduces a novel chromatographic matrix that effectively isolates and separates angiotensin I and II, key biomarkers involved in blood pressure regulation, from human serum. The system uses a hybrid combination matrix that selectively removes small molecular weight polypeptides while excluding large serum proteins. By integrating chelating agents with metal ions and polymers of varying molecular weights, the matrix enables highly efficient separation and quantification of these peptides. This process allows precise monitoring of angiotensin levels and has potential to help regulate or remove excess angiotensin II, which contributes to hypertension and related cardiovascular disorders.
Background:
Hypertension affects over one billion people globally and remains one of the leading risk factors for cardiovascular disease. Current clinical methods for detecting and quantifying angiotensin peptides often require multi-step, time-intensive procedures with limited accuracy at low concentrations. Existing technologies struggle to efficiently separate small peptides like angiotensin I and II from complex biological fluids due to interference by high molecular weight proteins. This innovative matrix overcomes this limitation by using a selective polymer barrier and metal chelation system that simplifies the separation process. This innovation reduces procedural steps, increases yield and purity, and provides an adaptable platform for both diagnostic and therapeutic applications involving hypertension and COVID-related ACE2 studies.
Applications:
- Biomedical diagnostics for hypertension and cardiovascular disease
- Angiotensin I and II concentrations monitoring in blood serum
- Development of peptide removal for extracorporeal blood perfusion devices
- Research tool for studying the Renin-Angiotensin System (RAS)
- Biomarker isolation research
Advantages:
- Simplifies separation of small peptides from complex biological samples
- Specific to angiotensin I and II biomarkers
- Compatible with existing chromatographic and analytical systems
- Expand existing therapeutics by reducing excess angiotensin II in circulation
- Scalable and cost-effective for research and clinical applications
